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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.007Cancers comprise a heterogeneous group of human diseases. Unifying characteristics include unchecked
abilities of tumor cells to proliferate and spread anatomically, and the presence of clonal advantageous
genetic changes. However, universal and highly speciﬁc tumor markers are unknown. Herein, we report
widespread long interspersed element-1 (LINE-1) repeat expression in human cancers. We show that
nearly half of all human cancers are immunoreactive for a LINE-1eencoded protein. LINE-1 protein
expression is a common feature of many types of high-grade malignant cancers, is rarely detected in
early stages of tumorigenesis, and is absent from normal somatic tissues. Studies have shown that
LINE-1 contributes to genetic changes in cancers, with somatic LINE-1 insertions seen in selected types
of human cancers, particularly colon cancer. We sought to correlate this observation with expression
of the LINE-1eencoded protein, open reading frame 1 protein, and found that LINE-1 open reading
frame 1 protein is a surprisingly broad, yet highly tumor-speciﬁc, antigen. (Am J Pathol 2014, 184:
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Disclosures: None declared.Global hypomethylation of genomic DNA is a well-
established feature of human cancers1 and may be related to
transcriptional derepression of noncoding and junk DNAs.
Indeed, transcription from satellite repeats has recently been
described in several common epithelial tumors compared with
normal tissue types.2 Herein, we focused on a commonly
occurring interspersed repeat in the human genome known to
encode protein, the long interspersed element-1 (LINE-1)
retrotransposon. Nearly one ﬁfth of our genome is composed
of LINE-1 sequences. LINE-1 is the only active autonomous
mobile DNA in humans. This activity traces to a subset of
approximately 100 genomic LINE-1 copies. These encode
proteins that participate in the replicative propagation of
LINE-1 and other interspersed repeats in the human germline.3stigative Pathology.
.Recent studies have shown that LINE-1 also contributes to
genetic changes in cancers, with somatic LINE-1 insertions
seen in selected types of human cancers, particularly colon
LINE-1 Is a Hallmark of Human Cancercancer.4,5 We sought to correlate this observation with
expression of the LINE-1eencoded protein, open reading
frame 1 protein (ORF1p), and found that the LINE-1ORF1p is
a surprisingly broad, yet highly tumor-speciﬁc, antigen.Materials and Methods
Tissue Specimens
Archived pathological samples collected for diagnostic
purposes were used for TMA assembly under Institutional
Review Boardeapproved protocols at Johns Hopkins Hos-
pital (Baltimore, MD). No identifying information was
associated with samples, and no medical record review was
conducted for the purposes of this study.IHC Data
Tissues were procured as routine surgical specimens,
embedded in parafﬁn, and ﬁxed in formalin. We examined
LINE-1 ORF1p antigenicity using immunohistochemistry
(IHC). A rabbit polyclonal LINE-1 ORF1p antibody used
was previously described.6 Additional antibody panel
included antibodies against Ki-67 (catalog 790-2910;
Ventana Medical Systems, Tucson, AZ; prediluted), TP53
(catalog 760-2542; Ventana Medical Systems; prediluted),
and monoclonal LINE-1 ORF1p antibody (seeMonoclonal
Anti-Human ORF1p Antibody). Brieﬂy, immunolabeling
with polyclonal LINE-1 ORF antibody was performed
using a standard overnight IHC protocol. Unstained sec-
tions (5 mm thick) of each TMA were baked for 25 minutes
at 65C. Slides were deparafﬁnized and hydrated before the
antigen retrieval step. Heat-induced antigen retrieval was
performed using EDTA buffer for 20 minutes. Slides were
then washed with normalizing buffer (pH 7.2 Tris-buffered
saline with Tween 20; Sigma-Aldrich, St. Louis, MO) and
incubated overnight with primary antibody LINE-1 ORF1p
(1:1000 dilution) in a 4C humid chamber. Incubation time
was set for 18 hours, after which slides were rinsed and
washed with Tris-buffered saline with Tween 20 for 15
minutes. Reaction was developed with a biotin-free Bond-
polymer detection system on a Bond-Leica autostainer
(Leica Microsystems, Bannockburn, IL). 30,30-Dia-
minobenzidine chromogen-substrate was used for visual-
ization of reaction. Slides were counterstained with
hematoxylin, dehydrated, and coverslipped. LINE-1
ORF1p immunoreactivity was expressed using a nominal
scale (ie, negative or positive). LINE-1 ORF1p intensity
was expressed semiquantitatively using a four-level
ordinal scale: 0, negative; 1, low; 2, intermediate; and
3, high. The level of LINE-1 ORF1p labeling was
expressed using a cell count score, which was estimated as
a percentage of LINE-1 ORF1pepositive lesional cells.
The LINE-1 staining score (product score) was calculated
by multiplying intensity and cell count scores.The American Journal of Pathology - ajp.amjpathol.orgMonoclonal Anti-Human ORF1p Antibody
Fifteen peptides from the LINE-1 ORF1p consensus
sequence (AAB60344.1, 338 amino acids) were selected as
potential surface epitopes antibody library antigens by
Abmart, Inc (Shanghai, China).
A synthetic gene encoding a multiple surface epitopes
antibody library was expressed in Escherichia coli with
proprietary immunogenicity enhancement factors. Each
immunogen was used to immunize three BALB/c mice. The
mouse with the best immune response was then used for
antibody development. The monoclonal LINE-1 ORF1p
antibody referenced herein targets the sequence corre-
sponding to amino acids 35 to 44 of LINE-1 ORF1p
(MENDFDELRE); this is in a region of relative divergence
between human and mouse LINE-1 ORF1p proteins. The
antibody puriﬁed by the manufacturer was validated in
immunoﬂuorescence, IHC, Western blot, and immunopre-
cipitation experiments against LINE-1 ORF1p expressed
from plasmid constructs.
Statistical Analysis
Correlation of LINE-1 immunolabeling with TP53 genetic
status was performed by using a binomial test. TP53 mu-
tations were determined by bidirectional sequencing in
pancreatic and ovarian carcinoma cases. TP53 status for
lung carcinomas and secondary glioblastomas (GBMs) was
estimated using a published IHC algorithm that closely
approximates TP53 mutational status when compared with
sequencing.7,8 For cases with both TP53 results available,
60 of 61 showed IHC and sequencing concordance. For
comparison of LINE-1 staining scores, we used a two-sided
Student’s t-test. LINE-1 immunoreactivity was scored by
two of the authors (N.R. and K.H.B.).
Results
LINE-1 Retrotransposon ORF1p Protein Is Not
Expressed in Normal Somatic Tissues
We used IHC to survey LINE-1 ORF1p protein expression
in a collection of TMAs of human primary malignant tu-
mors. We ﬁrst used a rabbit polyclonal antibody previously
shown to be speciﬁc by Western blot analysis.6 We vali-
dated staining conditions using a Tet-On inducible human
LINE-1 retrotransposon expression vector. Uninduced cells
showed no ORF1p immunoreactivity, whereas most
induced cells showed high levels of immunolabeling in a
speckled cytoplasmic pattern (Supplemental Figure S1). We
next examined ORF1p immunolabeling in adult testis and
embryonal carcinomas, which are reported to show LINE-1
protein expression.9,10 Consistent with these reports, we
detected low LINE-1 immunoreactivity in a few human
maturing spermatogonial cells and uniformly high levels of
LINE-1 immunoreactivity in embryonal carcinomas1281
Rodic et al(Supplemental Figure S2). We also developed a mouse
monoclonal antibody against an epitope of LINE-1 ORF1p,
which performed identically in these studies.
No LINE-1 protein expression was detected in mature
nonneoplastic somatic tissues by IHC (Figure 1) or a series
of Western blot analyses using tissue lysates (data not
shown). Ki-67 (MKI67) was used to demonstrate prolifer-
ating cells in lymph node germinal centers and proliferative
epithelial compartments of skin and gastrointestinal tract,
which showed no corresponding LINE-1 ORF1p immuno-
labeling (Supplemental Figure S3).
LINE-1 Retrotransposon ORF1p Protein Is a Hallmark of
Many Human Cancers
We next examined LINE-1 immunolabeling across a panel of
different human neoplasms (nZ 1027 cases) in a collection of
TMAs assembled from anatomical pathology cases from the
Sidney Kimmel Comprehensive Cancer Center at the Johns
Hopkins Hospital. Almost half (47%) of these were LINE-1
immunoreactive (n Z 482) (Supplemental Table S1).
LINE-1 ORF1p immunolabeling was restricted to cellularFigure 1 LINE-1eencoded protein ORF1p is undetectable in mature human so
Representative photomicrographs are shown in pairs, with normal tissues on the l
LINE-1 ORF1p immunoreactivity (brown) detected with a rabbit polyclonal ORF1p
cell carcinoma (B), lymphoma (C), hepatocellular carcinoma (D), lung carcinoma
cinoma (H). Original magniﬁcation, 160 (AeH). Scale bar Z 20 mm. N, norma
1282cytoplasm in most cases, frequently with a ﬁne punctate or
speckled pattern. Immunolabeling was seen in neoplastic cells
exclusively; no intervening benign components of tumors
were immunoreactive (Figure 1). LINE-1 immunolabeling
frequently highlighted the presence of isolated individual
neoplastic cells or small aggregates of cancer cells. Individual
cases showed little intratumoral variability in LINE-1
expression, but immunoreactivity varied between cases
(Supplemental Figure S4). Identical staining patterns were
seen using the polyclonal and monoclonal antibodies, and
there was a strong, linear relationship in staining intensities
comparing the two reagents [correlation coefﬁcient
(r)Z 0.746 (nZ 36)] (Supplemental Figure S5). Metastatic
disease was not associable with increased LINE-1 immuno-
labeling in the one tumor type in which this was studied.
LINE-1 immunoreactivity in matched primary and metastatic
pancreatic cancer specimens did not differ (nZ 27; primary
pancreatic cancer LINE-1 score Z 1.9; matched metastasis
LINE-1 scoreZ 1.9; PZ 0.86604).
We subdivided neoplasms on the basis of their primary site
of origin. Figure 2A illustrates the percentage of LINE-
1eimmunolabeling carcinomas within each group (n Z 608matic tissues and commonly expressed in a wide range of human cancers.
eft; tissues are counterstained (blue). Photomicrographs on the right show
antibody in various human neoplasms, including colon carcinoma (A), renal
(E), breast carcinoma (F), pancreatic carcinoma (G), and biliary tract car-
l tissue; T, tumor.
ajp.amjpathol.org - The American Journal of Pathology
Figure 2 LINE-1 ORF1p is present in a wide range of human neoplasms. A: LINE-1 expression as a percentage of LINE-1eimmunoreactive cases in different
primary tumor types. LINE-1 immunolabeling in low- versus high-grade mesenchymal tumors (B), lymphomas (C), pancreatic ductal neoplasms (D), and
astrocytic neoplasms (E), expressed as a percentage of cases. The number above each column in panels BeE designates the number of cases examined for
LINE-1 immunolabeling.
LINE-1 Is a Hallmark of Human Cancercases). Neoplasms most consistently LINE-1 positive include
invasive breast carcinomas (66 of 68 LINE-1epositive cases;
97% LINE-1 positive), high-grade ovarian carcinomas (29 of
31 LINE-1epositive cases; 93.5% LINE-1 positive), and
pancreatic ductal adenocarcinomas (56 of 63 LINE-1epositive
cases; 89% LINE-1 positive). Carcinomas originating in the
endometrium, biliary tract, esophagus, bladder, head and neck,
lung, and colon were frequently LINE-1 immunoreactive
(mean, 61% LINE-1 positive). Conversely, carcinomas that
originated in the kidney, liver, cervix, and prostate infrequently
express LINE-1 ORF1p (mean, 24% positive). The intensity of
immunoreactivity was highest in cancer types with relatively
high overall proportions of LINE-1epositive cases. More
LINE-1 immunolabeling was seen in histologically high-grade
sarcomas, lymphomas, pancreatic carcinomas, and secondary
GBMs (Figure 2, BeE). The correlation between LINE-1
expression and histological hallmarks of aggressive neo-
plasms suggests that LINE-1 expression may be an acquired
feature not seen frequently in early preneoplastic lesions or
low-grade tumors, but rather restricted to high-grade lesions at
more advanced phases of tumorigenesis.The American Journal of Pathology - ajp.amjpathol.orgLINE-1 Retrotransposon ORF1p Expression Occurs More
Commonly in TP53-Deﬁcient Human Cancers
To test the hypothesis that acquired mutations in tumor-
suppressor genes may correlate with LINE-1 expression, we
implemented a regression analysis comparing the percent-
age of LINE-1epositive cases we observed with the mean
reported TP53 mutation rates for different primary tumor
types. This suggested a positive correlation between LINE-1
immunolabeling and TP53 deﬁciency (P Z 0.02)
(Figure 3A and Supplemental Table S2).11e16 We examined
this relationship further using speciﬁc lung, pancreatic, and
ovarian carcinoma cases in which TP53 loss of function was
determined by sequencing and supported by IHC labeling of
overexpression of the mutated protein (Figure 3, B and C).
In lung carcinoma, LINE-1 expression was associated with
TP53 deﬁciency (n Z 85, P Z 0.035, binomial test). This
was also true in pancreatic and ovarian carcinomas in which
many cases expressed LINE-1 and were TP53 deﬁcient
(pancreas, n Z 36, P < 106; ovary, n Z 25, P < 105).
Notably, LINE-1eimmunoreactive lung and pancreatic1283
Figure 3 LINE-1 expression correlates with TP53 deﬁciency. A: Com-
parison of published TP53 mutation rates versus LINE-1 immunolabeling in
different carcinomas. B and C: A diagram (B) and representative photomi-
crographs (B) depicting LINE-1 immunolabeling and TP53 deﬁciency in lung
carcinomas, pancreatic carcinomas, ovarian carcinomas, and secondary
GBMs. Immunoreactivity for TP53 is an indicator of overexpression of a
mutated protein. The number of cases is denoted on the x axis of the bar
graph. *P < 0.05, based on the binomial test. Original magniﬁcation, 160
(AeC). Scale bar Z 20 mm. N, normal tissue; T, tumor.
Rodic et alcancers with TP53 deﬁciency also had higher LINE-1
staining intensity scores compared with LINE-1epositive
cases with wild-type TP53 (n Z 85, P < 0.05, two-tailed
Student’s t-test, and n Z 36, P < 0.05, respectively)
(Supplemental Figure S6, A and B).1284Glial tumors provide an illustrative example of the rela-
tionship between LINE-1 protein expression, histological
grade, and TP53 deﬁciency. We examined 244 astrocytic
neoplasms, which were overall infrequently LINE-1 positive
(mean, 20%) (Supplemental Table S1). Low-grade pilocytic
astrocytomas were rarely LINE-1 positive [1 (1.5%) of 67].
Intermediate-grade brain cancers, diffuse astrocytomas, and
clinically aggressive anaplastic astrocytomas expressed LINE-
1 protein infrequently [3 (8%) of 39 LINE-1epositive cases].
High-grade GBMs expressed LINE-1 more commonly (46
(33%) of 138 LINE-1epositive cases), albeit less frequently,
than high-grade carcinomas. We then separated GBMs into
primary (de novo) cases and secondary cases; the latter are
thought to arise from progression of antecedent low- and
intermediate-grade astrocytomas and, more frequently, harbor
TP53mutations.17We sawmany LINE-1epositive secondary
GBMs [29 (74%) of 39 cases]. In secondary GBMs, we
observed an association between LINE-1 immunoreactivity
and TP53-deﬁcient genetic background (nZ 39, PZ 0.015)
(Figure 3B and Supplemental Figure S6C).Discussion
Our observation that LINE-1 expression is a hallmark of
histologically aggressive cancers extends prior studies of
LINE-1 in cancer. Several groups have described hypo-
methylation of genomic LINE-1 sequences in a variety of
tumor types, including breast, colon, hepatocellular, pros-
tate, and neuroendocrine tumors.2,18e21
LINE-1 may contribute to genetic lesions in tumorigen-
esis through isolated activity of its encoded endonuclease or
by promoting new LINE-1 insertions that affect gene
expression. Evidence for the latter has been described by
targeted sequencing in colorectal cancers,4,5 lung cancers,22
and hepatocellular carcinomas23 and by analysis of whole-
genome sequences of colorectal, ovarian, and pancreatic
cancers.4 Direct comparisons of ORF1p expression levels
and somatic retrotransposition rates are needed; presumably,
new transposition events require a combination of aberrant
LINE-1 expression and other host conditions permissive for
transposition.
Although nuclear localization of a portion of LINE-
1eencoded protein is required for transposition, we pri-
marily observe a punctate cytoplasmic pattern of LINE-1
ORF1p immunolabeling in most cases. This largely agrees
with published observations, from both in vitro expression
of LINE-1 constructs used for retrotransposition assays24
and human tumors. However, two groups have described
a small fraction, approximately 5%, of human breast carci-
nomas displaying nuclear LINE-1 ORF1p immunolabel-
ing.6,25 More important, the same groups associated nuclear
immunolabeling with poor clinical outcomes. It will be of
considerable interest to enhance our sensitivity for detecting
nuclear LINE-1 ORF1p and investigate whether this corre-
sponds to somatic LINE-1 retrotransposition in tumors.ajp.amjpathol.org - The American Journal of Pathology
LINE-1 Is a Hallmark of Human CancerLINE-1 ORF1p may have clinical utility as a neoplastic
marker. It is broadly expressed in a wide variety of high-grade
human neoplasms, including highly lethal malignancies in
which early detection remains a clinical challenge. How many
genomic templates contribute to immunoreactivity for ORF1p
and whether interpatient heterogeneity is related to differences
in the inherited complement of active genomic LINE-1 se-
quences remain unknown. More important, we report minimal
to no intratumoral heterogeneity and similar LINE-1 ORF1p
immunolabeling in matched primary and metastatic speci-
mens. These ﬁndings are in agreement with a prior study by
Matsunoki et al,26 who reported little intrapatient heteroge-
neity in genomic LINE-1methylation in colorectal carcinomas
and metastatic samples. This property may make LINE-1
ORF1p expression useful in detecting residual disease and in
evaluating small specimens or those limited by rare lesional
cells. It is also possible that LINE-1 can be targeted in thera-
peutic interventions, developed either to prevent roles LINE-1
plays in clonal evolution of transformed cells or to potentiate
LINE-1 expression to promote cell lethal genotoxicity.
Our data indicate a strong, but imperfect, correlation
between TP53 mutation and LINE-1 expression. Congruous
observations have been made recently in colorectal carci-
nomas, which show a tendency for LINE-1 DNA hypo-
methylation in TP53-deﬁcient tumors.27 Thus, although the
LINE-1 promoter can be bound and transcriptionally acti-
vated by p53 in vitro,28 it appears that this is dispensable for
LINE-1 activity in TP53-mutated tumors and that other
factors are primary determinants in the relationship between
LINE-1 expression and the p53 pathway. One model is that
loss of TP53 promotes the viability and proliferative po-
tential of LINE-1eexpressing cells, perhaps by escape from
p53-mediated responses to LINE-1einduced DNA damage.
In support of this, studies enforcing ectopic expression of
LINE-1 have described double-stranded DNA breaks,
cytotoxicity, and apoptosis in TP53 wild-type cells.24,29,30
However, although TP53 loss may promote LINE-1 trans-
position, LINE-1 can be expressed and transpose with TP53
intact.24,31,32 Interestingly, TP53 control of interspersed
repeat expression may extend beyond LINE-1. Leonova
et al33 have recently shown in mouse that DNA hypo-
methylation causes massive accumulation of short inter-
spersed element transcription and double-stranded RNA
accumulation speciﬁcally in TP53-deﬁcient cells.
In conclusion, we estimate that as many as half of human
cancers express ORF1p. Within many tumor classiﬁcation
schemes, we associate LINE-1 expression with higher his-
tological grades and deﬁciency of the TP53 tumor
suppressor.Acknowledgments
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